Tau aggregates are present in several neurodegenerative diseases and correlate with the severity of memory deficit in AD (Alzheimer's disease). However, the triggers of tau aggregation and tau-induced neurodegeneration are still elusive. The impairment of protein-degradation systems might play a role in such processes, as these pathways normally keep tau levels at a low level which may prevent aggregation. Some proteases can process tau and thus contribute to tau aggregation by generating amyloidogenic fragments, but the complete clearance of tau mainly relies on the UPS (ubiquitin-proteasome system) and the ALS (autophagy-lysosome system). In the present paper, we focus on the regulation of the degradation of tau by the UPS and ALS and its relation to tau aggregation. We anticipate that stimulation of these two protein-degradation systems might be a potential therapeutic strategy for AD and other tauopathies.
Introduction
Tau aggregation is a characteristic feature of several neurodegenerative diseases including AD (Alzheimer's disease) [1] [2] [3] . To date, the mechanism of tau aggregation remains elusive. Several contributing factors may be envisaged, including the elevation of tau concentration and the generation of amyloidogenic fragments. Tau concentrations could rise because of a failure in the protein-degradation systems (based on autophagy, proteasomes or other proteases), or aggregation-prone fragments could stem from the activation of proteases.
The focus of the present review is on the autophagybased and proteasome-based degradation systems [ALS (autophagy-lysosome system) and UPS (ubiquitinproteasome system)], the two major pathways involved in the clearance of proteins in mammalian cells. The cleavage of tau by other proteases was reviewed recently [4] , but some new developments are briefly summarized in the present paper. Over the years several proteases [such as calpain, caspases 3, 6 and 9, cathepsins D and L, and PSA (puromycin-sensitive aminopeptidase)] have been reported to process tau. The limited proteolysis of tau by these proteases may contribute to neurodegeneration through several mechanisms. (i) The truncation of tau near the C-terminus may result in the generation of amyloidogenic fragments which initiate tau aggregation and therefore induce neurodegeneration. (ii) The cleavage of tau near the N-terminus may lead to the production of toxic tau fragments which cause neurodegeneration through unknown mechanisms (for a review, see [4] ). Such proteases might be potential therapeutic targets. However, controversial reports exist regarding the processing of tau by some of these proteases. For instance, a calpain-induced 17 kDa tau fragment assumed to be tau- has been claimed to be cytotoxic [5] [6] [7] , but according to our analysis the fragment generated by calpain is much smaller, tau-(125-230) instead of tau- , and shows no consistent toxicity [8] . Another example is PSA which was reported previously to degrade tau both in vivo and in vitro [9, 10] . However, a recent study provided evidence that PSA cannot directly process tau [11] . The authors suggested that digestion of tau by PSA in the earlier studies might arise from other proteases present as contaminations in isolated PSA. Subsequent in vivo studies reaffirmed that increasing PSA activity can eliminate accumulation of tau [12] , but the question remains whether this is a direct effect of PSA, as PSA can also activate autophagy [13] and tau is a substrate of autophagy (see below).
Degradation of tau by the proteasomal pathway
The proteasomal pathway is a major protein-degradation pathway that plays a key role in degrading short-lived and misfolded proteins [14] . The 26S proteasome is a multi-catalytic protease that is composed of three major subunits: one 20S catalytic core and two 19S regulatory caps [15] . The 20S catalytic core contains three types of subunits that execute trypsin-like, chymotrypsin-like and peptidylglutamyl-peptide hydrolysing activities. The 19S regulatory caps facilitate the access of the target protein to the 20S proteasome by unfolding the substrates and opening the catalytic channel. The canonical ubiquitinproteasome pathway involves two discrete steps: (i) covalent attachment of multiple ubiquitin molecules to the substrate via a three-step cascade mechanism involving ubiquitinactivating enzyme E1, ubiquitin-conjugating enzyme E2 and ubiquitin ligase E3; and (ii) degradation of the ubiquitinated protein by the 26S proteasome with the release of free and reusable ubiquitin [15] . This pathway degrades protein in an ATP-dependent and ubiquitin-dependent manner. The 20S proteasome may also exist in a free form which can digest proteins directly in an ATP-independent and ubiquitinindependent manner [16] .
Ubiquitination of tau
The ubiquitination of tau was first proposed about three decades ago, when ubiquitin was found to be a component of NFTs (neurofibrillary tangles) with an antibody against ubiquitin [17] [18] [19] 63 -linked polyubiquitin chains has also been reported [22, 23] ; however, it is unclear whether such ubiquitination exists in the human brain.
Remarkably, all reported ubiquitination sites of tau localize to the microtubule-binding region. It is known that the phosphorylation of tau at the microtubule-binding domains by MARK (microtubule-affinity regulating kinase) 2 regulates the association of tau with microtubules [24] . Other modifications in this domain, for example acetylation of tau at Lys 280 , impair tau-microtubule interactions as well and promote pathological tau aggregation [25] . Thus, by analogy, one would expect that the ubiquitination of tau in the repeat domain could interfere with the binding of tau to microtubules as well. Indeed, polyubiquitinated tau fails to interact with microtubules in HEK (human embryonic kidney)-293 cells [23] . However, the influence of ubiquitination of tau on microtubule assembly has not yet been examined in vitro.
So far, two E3 ubiquitin ligases, CHIP [C-terminus of HSC70 (heat-shock cognate 70)-interacting protein] and TRAF6 (tumour-necrosis-factor-receptor-associated factor 6), were found to ubiquitinate tau [23, [26] [27] [28] . Both ligases colocalize with NFTs in AD brain. In vitro experiments showed that CHIP could ubiquitinate tau through both ubiquitin Lys 48 and Lys 63 linkage [27] , whereas TRAF6 ubiquitinates tau only through ubiquitin Lys 63 linkage [23] . The lysine residues on tau ubiquitinated by these two ligases have not been determined. Therefore it is unclear whether these two ligases can ubiquitinate all known ubiquitination residues on tau or whether there are other ligases involved in tau ubiquitination. Contrary to the above evidence, Grune et al. [29] reported that they failed to detect any polyubiquitination of tau in in vitro ubiquitination assays. They therefore argued that tau is not regularly ubiquitinated under normal conditions. The causes of these contradictory results are unknown.
Although in vitro assays showed that CHIP can ubiquitinate recombinant tau [26, 27] , in cultured cells CHIP selectively ubiquitinates tau phosphorylated at prolinedirected serine/threonine sites [28, 30] , whereas phosphorylation at the KXGS (Lys-Xaa-Gly-Ser) motifs in the repeat domain prevents the ubiquitination of tau [30] . The mechanism of such selective ubiqutination remains unclear. Shimura et al. [28] proposed that this is due to the preferential binding of HSC70 to phosphorylated tau forming a complex that then is recognized by CHIP. On the other hand, other in vitro studies suggested that chaperones are not necessary for ubiquitination of tau by CHIP, i.e. HSP (heat-shock protein) 70 antagonizes CHIP ubiquitination of tau when overexpressed in HEK-293 cells [27] . Thus the binding of HSC70 to phosphorylated tau seems unlikely to be the reason for selective ubiqutination of tau. Since different chaperones (HSC70 compared with HSP70) were used in these studies, one cannot exclude the possibility that HSP70 and HSC70 function differentially in regulating CHIPmediated ubiquitination.
Ubiquitination enhances tau aggregation
The Lys 48 -linked polyubiquitin chains are regarded to be a signal for proteasomal degradation [31] . However, most of the insoluble PHF-tau isolated from AD brains was reported to be mono-ubiquitinated and only a minority is polyubiquitinated [20] . As mono-ubiquitination is not a strong signal for degradation [32] , the majority of PHF may not be targeted for proteasomal degradation. So far, the significance of mono-ubiquitination of insoluble PHF-tau is unknown. Notably, in that study, the authors failed to detect any ubiquitination of soluble tau, thus they proposed that tau was ubiquitinated after aggregation [20] . They also found that ubiquitin exists only in the mid-portion of neuropil threads and not at its ends [33] and proposed that tau may aggregate and deposit first, followed by its ubiquitination, while neuropil threads may extend at both ends. However, as described above, ubiquitinated soluble tau exists in AD brains [21, 34] . Thus ubiqutination of tau does not necessarily occur after aggregation. One alternative explanation would be that ubiquitination drives tau towards aggregation.
Indeed, growing evidence supports this view. First, overexpressing CHIP in cultured cells promotes the formation of tau aggregates which are polyubiquitinated [27, 28] . Secondly, promoting ubiquitination of tau by overexpression of Lys 63 or Lys 48 ubiquitin (i.e. ubiquitin mutants containing arginine substitutions on all lysine residues except the one at position 63 or 48 respectively) leads to tau-positive inclusions in SH-SY5Y cells overexpressing mutant tau [22] . Finally, knockout of CHIP results in accumulation of hyperphosphorylated tau, but not tau aggregation in transgenic mice, suggesting that ubiquitination probably is necessary for tau aggregation [35] . Taken together, these data suggest that ubiquitination enhances tau aggregation. In addition, levels of CHIP and HSP70 are increased in AD brain compared with normal controls, which would also support this view. However, in AD and also in a JNPL3 mouse brain tauopathy model, CHIP is inversely proportional to sarkosyl-insoluble tau accumulation, suggesting that CHIP may protect against NFT formation [36] . Therefore whether or not ubiqutination of tau enhances its aggregation requires further investigation.
An in vitro experiment that shows directly the influence of ubiqutination on tau fibrillization would help to clarify this issue. In addition, it would be of interest to know whether overexpressing CHIP enhances tau aggregation in vivo.
Contradictory reports on degradation of tau by the proteasome
In vitro, tau can be directly processed by the isolated 20S proteasome without ubiquitination, resulting in the generation of a series of degradation intermediates [37] . This is understandable considering tau's natively unfolded structure, so that unfolding by the non-catalytic proteasomal caps is not necessary. Phosphorylation of tau by GSK3β (glycogen synthase kinase 3β) has been reported to inhibit its proteolysis by the 20S proteasome [38] . However, whether tau is degraded by the proteasome in cells is a controversial issue. Some studies demonstrated that tau is a substrate of the proteasome [28, 30, 37, 39] , whereas others argued that the proteasome has little influence on tau degradation [40] [41] [42] [43] . The causes of these contradictions are not clear, but they may reflect the fact that the degradation of tau may be influenced by many conditions or factors.
First, in some of these studies, different cells were used, which might lead to different conclusions since the degradation of tau might proceed through different pathways. For instance, tau has been described as a substrate of the proteasome in several cancerous cell lines, but our results argued that tau is not degraded by the proteasome in mouse neuroblastoma cells (N2a) [40] . In addition, in primary neurons, tau is normally not degraded through the UPS either. It appears that the inhibition of the proteasomes has little influence on tau levels in cultured primary neurons [41] , and we found that suppression of the proteasome reduces tau levels in cultured neurons (rather than increasing it), because of the activation of macroautophagy [44] . In fact, the regulation of the protein degradation systems might differ in cancer cell lines and primary neurons. For example, rapamycin, an inhibitor of mTOR (mammalian target of rapamycin), has been successfully utilized to induce autophagy in cancer cell lines, but whether it stimulates autophagy in primary neurons is controversial [45] . Several groups have argued that rapamycin can induce autophagy in neurons [46, 47] , whereas others have demonstrated that rapamycin fails to stimulate autophagy in primary neurons [48] . Our own data are in line with the latter report, showing that rapamycin does not activate autophagy in cultured neurons [44] .
Secondly, different forms of tau might undergo different degradation pathways. In the same cell line, full-length tau may be degraded through the proteasomal pathways, whereas tau truncated at Asp 421 is preferentially degraded by autophagy [49] . Wild-type tau and mutant tau may be degraded through different mechanisms under certain conditions, as in vitro and in vivo studies showed that inhibition of HSP90 induces proteasomal degradation of mutant tau, but not of wild-type tau [50] .
Thirdly, post-translation modifications of tau might affect its degradation. For example, the phosphorylation state of tau has a significant influence on its degradation. As described above, phosphorylation in the repeat domain prevents tau ubiquitination by CHIP and its degradation through the proteasome pathway [30] . Other post-translational modifications have also been reported to influence tau degradation. For example, C-terminal truncation of tau behind Asp 421 by caspase 3 was reported to enhance autophagic rather than proteasomal degradation, acetylation (at residues 163, 174 and 180) or nitration-retarded tau degradation by proteasome [49, 51, 52] .
Finally, the state of aggregation of tau could influence its clearance. It is known that the narrow pore of the proteasome barrel precludes the clearance of oligomeric and aggregated proteins [53] . It has been reported that NFTs isolated from AD brain or formed in vitro by recombinant tau can inhibit proteasome activity [54] . In the triple transgenic mice, Aβ (amyloid β-peptide) immunotherapy leads to clearance of soluble tau at early stages by the UPS, but not of late hyperphosphorylated tau aggregates [55] .
Regulation of proteasomal degradation of tau by the co-ordination of CHIP and the HSP70/HSP90 chaperone systems The HSP70 chaperone system including the constitutively expressed HSC70 and stress-inducible forms of HSP70 are central players in protein folding and proteostasis control [56] . Indeed, HSP70/HSP90 appear to play a role in refolding tau and thereby preventing tau aggregation, as tau aggregates were found to inversely correlate with HSP70/HSP90 in tau transgenic mouse and AD brains [57] . In addition, HSP70 is involved in tau metabolism, as (i) induction of HSP70 reduces tau levels in cultured cells; (ii) the endogenous mouse tau level is significantly reduced in HSP70 transgenic mice compared with non-transgenic control mice [27] ; (iii) HSP70 co-chaperones, particularly BAG (BCL2-associated athanogene)-1 and BAG-2, are also involved in tau degradation [58, 59] .
Human BAG-1 has three isoforms including BAG-1S, BAG-1M and BAG-1L [60] . In AD brains, the BAG-1M isoform is up-regulated in the hippocampus, which might contribute to tau accumulation [61] . Overexpression of BAG-1 does not affect tau ubiquitination and ubiquitinated tau degradation [58] . However, it inhibits the degradation of tau protein by the 20S proteasome, which, in contrast with the canonical 26S proteasome, digests proteins directly in an ATP-independent and ubiquitin-independent manner without unfolding the substrates by the 19S regulatory subunits [58] . This might occur because BAG-1 can activate the ATPase domain on HSC70 and thus induce substrate release [62] . Consistent with this view, inhibitors of the HSP70 ATPase can induce proteasome-dependent tau degradation, and, conversely, HSP70 activators can preserve tau levels in a cell model [63] . Notably, MB (Methylene Blue), a well-known tau aggregation inhibitor [64] [65] [66] , and its demethylated analogue methylthionine (e.g. azure C), were reported to be inhibitors of HSP70 ATPase, which induce reduction of both total tau and tau phosphorylated at Ser 396 /Ser 404 in HeLa cells overexpressing human tau [63] . These authors showed that proteasomes play a dominant role in azure C-induced tau reduction because the proteasome inhibitor epoxomicin abrogates its effects (the influence of proteasome inhibition on MB-induced tau reduction was not addressed directly in this study) [63] . In contrast, we found that autophagy is involved in MB-induced reduction of cellular tau levels [67] , consistent with a recent report that MB reduces tau levels through stimulating autophagy in cell models and in transgenic mouse model of tauopathy [68] .
BAG-2 belongs to the same BAG family as BAG-1, but it regulates tau degradation through different mechanisms. In contrast with BAG-1, overexpression of BAG-2 does not increase tau levels, but preferentially reduces insoluble and phosphorylated tau levels [59] . Similarly, BAG-2 also regulates the degradation of tau through the ubiquitinindependent proteasome pathway. However, being a CHIP inhibitor [69] , BAG-2 prevents the ubiquitination of tau [59] , in contrast with BAG-1.
Although HSP70 is involved in the ubiquitination of tau by CHIP, HSP70 seems to play a major role in regulating tau degradation through the ubiquitin-independent pathway. In fact, overexpression of HSP70 in cells appears to attenuate the ubiquitination of tau induced by CHIP [27] . Thus CHIP may regulate tau degradation mainly through interaction with HSP90, as described below.
HSP90 is a molecular chaperone that is involved in the folding and stabilization of many client proteins. In 2007, two groups simultaneously reported that HSP90 plays a role in tau degradation, as HSP90 inhibitors reduce tau levels both in cultured cells or in vivo in transgenic mice [30, 50] . However, some of the data from these two studies are not consistent. Luo et al. [50] showed that inhibition of HSP90 reduces the level of mutant tau, but not wild-type tau, whereas Dickey et al. [30] showed that inhibition of HSP90 selectively degrades tau phosphorylated in the regions flanking the repeat domain, but not tau phosphorylated at the repeat domain, regardless of wild-type or mutant tau. The causes of these inconsistencies are not clear, but could be due to other off-target effects of the different inhibitors used in these studies.
CHIP appears to be critical for the inhibition of HSP90-induced tau degradation, as knockout of CHIP abrogates such effects [30] . Phosphorylation in the repeat domain prevents the interaction of CHIP with tau, which may be the cause of the lack of proteasomal degradation of such phosphorylated tau species. Phosphorylation of tau with GSK3β increases the interaction of tau with HSP90, indicating that tau phosphorylated in the flanking regions outside the repeat domain is a preferred client of HSP90 [30] . Knocking down the expression of HSP90 enhances the interaction of tau with CHIP. Collectively, the authors proposed that tau phosphorylated in the flanking region is recognized by HSP90 (together with co-chaperones) in an attempt at refolding, which inhibits its ubiquitination by CHIP and degradation through the proteasome. When the refolding is suppressed by HSP90 inhibitors, this phosphorylated tau is delivered to CHIP for ubiquitination and then subsequent proteasomal degradation.
Influence of tau on proteasome activity
Although tau is a substrate of the proteasome (at least under some conditions), tau aggregates can adversely affect proteasome activity. PHFs isolated from AD brains or formed by recombinant tau have been reported to suppress proteasomal activity in vitro, and in AD, proteasomal activity is significantly reduced [54, 70] . Such a loss of activity is not due to a decrease in the proteasome protein, but to the direct inhibition by PHFs. The proposed explanation is that PHFs associate with proteasomes and the amount of PHFs associated with proteasomes inversely correlates with proteasomal activity [54] . As a result, the inhibition of proteasome could contribute further to tau accumulation and aggregation. Thus tau aggregation and proteasome inhibition could form a positive-feedback loop which might accelerate neurodegeneration.
Degradation of tau by the ALS
Besides the proteasomal pathway, another major route of protein degradation is the autophagy-lysosome pathway [14] . On the basis of the different mechanisms of delivering substrates to lysosomes, there are three types of autophagy: microautophagy, macroautophagy and chaperone-mediated autophagy. In microautophagy, the lysosomal membrane directly engulfs part of the cytosol. So far, this pathway has not been well studied. Macroautophagy (hereinafter referred to simply as autophagy) is the main pathway for eukaryotic cells to degrade long-lived proteins and organelles. In this pathway, a small volume of the cytosol is sequestered into a double membrane vesicle called the autophagosome, which then fuses with the lysosome. Chaperone-mediated autophagy is a type of selective autophagy targeting soluble cytosolic proteins containing a motif biochemically related to the pentapeptide KFERQ ( Lys-Phe-Glu-Arg-Gln) [71] . The substrates are recognized by HSC70 and transferred to the lysosomal membrane, where they bind to the LAMP2A (lysosome-associated membrane protein 2A) receptor and are then translocated into the lysosomal lumen and degraded [71] . Notably, tau contains two KFERQ homology motifs in the repeat domains [40] .
Tau is a long-lived protein, and as such would be expected to be degraded in lysosomes. In AD brain, Alz-50-immunoreactivity co-localizes with lysosomes [72, 73] . Inhibition of lysosomal proteases with chloroquine in rat organotypic entorhino-hippocampal slices induces tau to form tangle-like structures [74] . Tau accumulates in the lysosomal compartment in muscles in CM (chloroquine myopathy) induced by long-term administration of chloroquine to rats [75, 76] . Interestingly, NFTs are found in NPC (Niemann-Pick type C), a lysosomal storage disease that results from defects in lysosomal function, suggesting that impairment of lysosomes might be one of the causes of tau aggregation.
Using inducible cell models of tauopathy, we have shown that autophagy is involved in the degradation of both soluble and insoluble tau [40] . Unlike the proteasome, autophagy degrades tau regardless of phosphorylation. Tau phosphorylated at the KXGS motifs of the repeat domain, which cannot be degraded by the UPS, is efficiently degraded by autophagy. Furthermore, we found that, in cultured primary neurons, endogenous tau is also degraded by autophagy, not by the proteasome [44] . Consistent with this, perturbation of autophagy enhances tau aggregation in a cell model overexpressing human tau [77] . Activation of autophagy with rapamycin reduces tau levels in cultured cells and also in vivo in a Drosophila model overexpressing human tau [78] . Furthermore, stimulation of autophagy with trehalose ameliorates tau pathology in parkin-knockout and tau-overexpressing mice, also indicating the involvement of autophagy in tau degradation [44, 79] .
Apart from degradation, we found that chaperonemediated autophagy is also involved in the proteolytic processing of tau in a cell model of tauopathy [40] . In this cell model, the role of chaperone-mediated autophagy and autophagy in tau aggregation is antagonistic. While (macro-)autophagy degrades tau to prevent aggregation, chaperone-mediated autophagy helps delivery of tau fragments to lysosomes for generation of more aggregationprone fragments which subsequently induce more tau aggregation.
Although tau is a substrate of autophagy, it can also modulate autophagy pathways under certain conditions. The expression of mutant human tau in cultured Aplysia neurons leads to a dramatic accumulation of autophagosomes and lysosomes [80] . In a line of transgenic mice overexpressing human mutant (P301L) tau, autophagic vacuoles were found to accumulate in neurons [81] . In transgenic mice expressing tau with G272V, P301L and R406W mutations (which occur in human FTDP17), an increase in the number of lysosomal complexes was detected in neurons [82] . Both studies indicate that tau pathology may lead to impairment of the ALS. Knockdown of tau expression in NPC1-deficient fibroblasts significantly decreases autophagic induction and flux, while having no effect on the autophagic pathway in control cells. Thus the normal function of tau seems to be critical to the induction of autophagy in NPC1 deficiency [83] .
Relationship between tau degradation and aggregation
The impairment of protein degradation used to be considered secondary to tau aggregation, assuming that tau aggregates might inhibit proteasomes [54] . Alternatively, emerging evidence suggests that impairment of protein degradation systems could be the cause of protein aggregation. Slight overexpression of mouse tau induces tau aggregation in transgenic mice [84] . Overexpression of tau in cultured neurons results in mis-sorting of tau to dendrites, which leads to hyperphosphorylation of tau as well [85, 86] . These studies suggest that the increased level of tau is likely to induce a cascade leading to aggregation. Thus the impairment of the protein-degradation systems that results in the accumulation of tau might be the cause of tau aggregation. In line with this view, conditional knockout of autophagy in the CNS (central nervous system) results in aggregation of polyubiquitinated proteins and neurodegeneration. This indicates that a compromise of protein degradation is sufficient to induce protein aggregation [87, 88] . It will therefore be interesting to examine in more detail the relative contributions of inhibiting the UPS or ALS on tau aggregation in vivo.
Conclusions and perspectives
The data reviewed in the present paper show that tau may be degraded by both the UPS and the ALS under different conditions and in different cell types. The HSP70/HSP90 systems play a critical role in the regulation of tau degradation through the proteasome. HSP70 interacting with co-chaperones BAG-1 and BAG-2 mainly regulates the ubiqutin-independent degradation of tau. HSP90 forming a complex with CHIP selectively recognizes and degrades tau phosphorylated in the flanking regions, but not in the repeat domain itself. Notably, ubiquitination of tau via CHIP seems to play a role in inducing tau aggregation.
Apart from tau aggregation, protein-degradation systems are also involved in the accumulation of Aβ, another hallmark of AD [89] . Emerging evidence shows that decreased clearance rather than enhanced generation may in fact be the cause of accumulation of Aβ in human brain [90] . Impairment of autophagy elevates Aβ levels [91] , activation of autophagy reduces Aβ, and Aβ reduces autophagy by increasing mTOR activity [92, 93] . As there is impairment of autophagy in AD, this might be one of the culprits leading to Aβ accumulation. Notably, Aβ can cause inhibition of both the UPS and ALS [93, 94] . Thus there seems to a positive feedback between Aβ accumulation and impairment of the protein-degradation systems, which might accelerate the progress of neurodegeneration.
The protein-degradation systems tend to decline with age [95] [96] [97] [98] , and, consistent with this, Aβ and tau aggregates can also be found in aging human brains not (yet) affected by AD, suggesting that they might be products of a normal aging process. Thus the pathogenesis of sporadic AD might be depicted by the relationships shown in Figure 1 . With age, the activity of the protein degradation systems (including the UPS and ALS) decreases, which leads to accumulation of Aβ and tau. The accumulation of Aβ interferes with both degradation systems and thus further exacerbates their impairment. The accumulation of tau might then result in mis-sorting and hyperphosphorylation and other modifications which finally lead to tau aggregation. Tau aggregates might bind to proteasomes and inhibit proteasome activity. Aggregation of tau and accumulation of Aβ both induce neurodegeneration. The compromise of the protein-degradation systems itself might also induce neurodegeneration through other unknown mechanisms independently of Aβ and tau. One open question with this hypothesis is that the age-dependent reduction in the proteindegradation systems seems to be a normal aging process, but only a fraction of people develop AD. This might be explained by other mechanisms that regulate the activity of the proteindegradation systems.
If the compromise of the protein-degradation systems plays a critical role in AD, a potential therapeutic strategy would be to promote the activity of these systems. Activation of autophagy has been successfully used to rescue neurodegeneration in transgenic mice and cell models [44, 93, 99] . Low-molecular-mass compounds activating proteasomes have been successfully developed [100] . In the future, it will be of interest to test whether such compounds can rescue neurodegeneration in AD.
